Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia

[1]  M. Glogowska,et al.  The psychological journey of weight gain in psychosis , 2022, Psychology and psychotherapy.

[2]  S. Leucht,et al.  Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia , 2022, European Archives of Psychiatry and Clinical Neuroscience.

[3]  T. Furukawa,et al.  Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. , 2021, The lancet. Psychiatry.

[4]  C. Correll,et al.  Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis , 2021, npj Schizophrenia.

[5]  T. Furukawa,et al.  How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. , 2021, Schizophrenia bulletin.

[6]  S. Heres,et al.  Barriers and facilitators of shared decision making in acutely ill inpatients with schizophrenia—Qualitative findings from the intervention group of a randomised‐controlled trial , 2021, Health expectations : an international journal of public participation in health care and health policy.

[7]  P. Weiden,et al.  Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey , 2020, Patient preference and adherence.

[8]  S. Heres,et al.  Implementing shared decision-making on acute psychiatric wards: a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS) , 2020, Epidemiology and Psychiatric Sciences.

[9]  Andrea Cipriani,et al.  The Kilim plot: A tool for visualizing network meta‐analysis results for multiple outcomes , 2020, Research synthesis methods.

[10]  E. Steyerberg,et al.  A two-stage prediction model for heterogeneous effects of many treatment options: application to drugs for Multiple Sclerosis , 2020, 2004.13464.

[11]  Philipp Mayring.  Qualitative Inhaltsanalyse , 2019, Handbuch Qualitative Forschung in der Psychologie.

[12]  Dimitris Mavridis,et al.  Extensions of the probabilistic ranking metrics of competing treatments in network meta‐analysis to reflect clinically important relative differences on many outcomes , 2019, Biometrical journal. Biometrische Zeitschrift.

[13]  Andrea Cipriani,et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis , 2019, The Lancet.

[14]  Sharon E. Straus,et al.  The number needed to treat in pairwise and network meta-analysis and its graphical representation. , 2019, Journal of Clinical Epidemiology.

[15]  P. Weiden,et al.  Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia , 2018, BMC Psychiatry.

[16]  T. Furukawa,et al.  Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta‐analysis , 2018, World psychiatry : official journal of the World Psychiatric Association.

[17]  C. Correll,et al.  The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study , 2018, Schizophrenia bulletin.

[18]  C. Kuo,et al.  Early improvement in PANSS‐30, PANSS‐8, and PANSS‐6 scores predicts ultimate response and remission during acute treatment of schizophrenia , 2018, Acta psychiatrica Scandinavica.

[19]  Karen R. Sepucha,et al.  Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist , 2017, BMJ Quality & Safety.

[20]  Martin Härter,et al.  A three-talk model for shared decision making: multistage consultation process , 2017, British Medical Journal.

[21]  Gordon H Guyatt,et al.  Progress in evidence-based medicine: a quarter century on , 2017, The Lancet.

[22]  S. Heres,et al.  Shared decision making PLUS – a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS) , 2017, BMC Psychiatry.

[23]  M. Albus,et al.  Training patients with schizophrenia to share decisions with their psychiatrists: a randomized-controlled trial , 2017, Social Psychiatry and Psychiatric Epidemiology.

[24]  T. Furukawa,et al.  Network meta-analyses should be the highest level of evidence in treatment guidelines , 2016, European Archives of Psychiatry and Clinical Neuroscience.

[25]  C. Correll,et al.  PANSS‐6: a brief rating scale for the measurement of severity in schizophrenia , 2016, Acta psychiatrica Scandinavica.

[26]  G. Guyatt,et al.  Do clinicians understand the size of treatment effects? A randomized survey across 8 countries , 2015, Canadian Medical Association Journal.

[27]  P. Kroonenberg,et al.  Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care , 2015, PloS one.

[28]  M. Bühner,et al.  What can patients do to facilitate shared decision making? A qualitative study of patients with depression or schizophrenia and psychiatrists , 2015, Social Psychiatry and Psychiatric Epidemiology.

[29]  R. Newcombe,et al.  Toward Minimum Standards for Certifying Patient Decision Aids , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  Jan Scott,et al.  Patient Related Outcome Measures Dovepress Nonadherence with Antipsychotic Medication in Schizophrenia: Challenges and Management Strategies , 2022 .

[31]  Peter McCulloch,et al.  Understanding regional variation in the use of surgery , 2014 .

[32]  B. O’Donoghue,et al.  Service users' perceptions about their hospital admission elicited by service user-researchers or by clinicians. , 2013, Psychiatric services.

[33]  D. Rennie,et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.

[34]  M. Härter,et al.  Development and psychometric properties of the Shared Decision Making Questionnaire--physician version (SDM-Q-Doc). , 2012, Patient education and counseling.

[35]  R. Rosenheck,et al.  Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). , 2012, The Journal of clinical psychiatry.

[36]  J. Kane,et al.  Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses , 2011, Psychological Medicine.

[37]  A. Serretti,et al.  A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics , 2011, International clinical psychopharmacology.

[38]  T. Furukawa,et al.  Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials , 2011, Schizophrenia Research.

[39]  M. Bühner,et al.  Drowning in Numbers–what Psychiatrists Mean when Talking to Patients about Probabilities of Risks and Benefits of Medication , 2010, European Psychiatry.

[40]  Martin Härter,et al.  The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. , 2010, Patient education and counseling.

[41]  C. Adams,et al.  Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used , 2010, British Journal of Psychiatry.

[42]  D. Revicki,et al.  Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients , 2010, Schizophrenia Research.

[43]  S. Leucht,et al.  How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? , 2010, European Neuropsychopharmacology.

[44]  W. Fleischhacker,et al.  Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia , 2009, Schizophrenia Research.

[45]  M. Ziegler,et al.  Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. , 2009, Psychiatric services.

[46]  J. Moncrieff,et al.  ACTA PSYCHIATRICA , 2006 .

[47]  M. Petticrew,et al.  Developing and evaluating complex interventions: the new Medical Research Council guidance , 2008, BMJ : British Medical Journal.

[48]  J. Os,et al.  Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? , 2008, Psychoneuroendocrinology.

[49]  Werner Kissling,et al.  Patients’ and Psychiatrists’ Perceptions of Clinical Decisions During Schizophrenia Treatment , 2008, The Journal of nervous and mental disease.

[50]  E. Brähler,et al.  Teststatistische Prüfung und Normierung der deutschen Versionen des EUROHIS-QOL Lebensqualität-Index und des WHO-5 Wohlbefindens-Index , 2007 .

[51]  S. Leucht,et al.  Shared decision making for in‐patients with schizophrenia , 2006, Acta psychiatrica Scandinavica.

[52]  S. Leucht,et al.  Psychiatric decision making in the adoption of a new antipsychotic in Germany. , 2006, Psychiatric services.

[53]  S. Leucht,et al.  Medical decision making in antipsychotic drug choice for schizophrenia. , 2004, The American journal of psychiatry.

[54]  R. Emsley,et al.  Evidence-based pharmacotherapy of schizophrenia. , 2004, The international journal of neuropsychopharmacology.

[55]  Laurence B McCullough,et al.  A Typology of Shared Decision Making, Informed Consent, and Simple Consent , 2004, Annals of Internal Medicine.

[56]  S. Leucht,et al.  Shared decision making in psychiatry , 2003, Acta psychiatrica Scandinavica.

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[58]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.

[59]  A. Sergejew,et al.  Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses , 2000, Schizophrenia Research.

[60]  P. Morosini,et al.  Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning , 2000, Acta psychiatrica Scandinavica.

[61]  O. Benkert,et al.  KOMPENDIUM DER PSYCHIATRISCHEN PHARMAKOTHERAPIE , 1998 .

[62]  M. Slade,et al.  A self‐report Insight Scale for psychosis: reliability, validity and sensitivity to change , 1994, Acta psychiatrica Scandinavica.

[63]  A. Ash,et al.  Measuring patients' desire for autonomy: decision making and information-seeking preferences among medical patients. , 1989, Journal of general internal medicine.

[64]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[65]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[66]  T. Hogan,et al.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.